We would love to hear your thoughts about our site and services, please take our survey here.
Agree PB. But in biotech terms not long to wait for very important news and some little fillers along the way.
I remember piling into Synairgen at 10p thinking why isn't everybody doing so. It stayed low for a good while before it took off in a big way. Feels like that might be happening here too? But of course, things can change quickly.
DYOR
Exactly EE,
I have been in contact with an AIM CFO this week who stated that the market will improve. Common sense really but of course it is all about the when. I am happy to wait. When this happens we should expect a fair and not derisory valuation. Not only this, as Funds, private investors etc re-enter the market they will presumably choose high quality opportunities. Surely Sclp are in that category if not towards the top of the list?
Emerald Carrots,
Your question, why does so and so keep posting...
Your answer:
Provocateur
Meaning of provocateur in English someone who intentionally causes arguments or discussions, or intentionally makes other people feel angry, offended, or uncomfortable: He is a provocateur not afraid of confronting his own audience.
Now a foundational rule of communication between two parties: transactions will continue indefinitely as long as transactions are complimentary. This is to say that whether you are wishing each other a good day or arguing about the time of day, each are definitions of complimentary transactions. In other words, as long as you feel the need to explain, they feel the need to provoke, or either one of you or both wants to have the last word then this ongoing transaction will continue, and unfortunately for the rest of us, it looks like it will continue indefinitely...
Good day to you both.
If you do not wish to take part in a transaction with any particular party, you do not have to
Not really JH. Amati have sold a few in previous years in many companies. It is part of what they do year in year out.
It is that time of year - they have to pay the piper
We should remember that this is not just Moditope vs cancer. The setting in which this contest takes place is the human body. So until time is called there is all to play for and we should remember that it is the body itself will have an enormous influence on outcomes and not just the drug or cancer. It is not just straight win or lose imo.
We know that Scancell were looking for a partner for Covidity. It is my opinion that they may have reached a dead end or they have been lucid enough to switch focus to SCOPE and MODIFY. Is it possible that Texas Biomed were simply offered or requested a development opportunity. If only for research purposes? May not be a dead duck after all and could be one for the long distant future.